Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)
CompletedOBSERVATIONAL
Enrollment
189,629
Participants
Timeline
Start Date
February 6, 2007
Primary Completion Date
December 13, 2010
Study Completion Date
December 13, 2010
Conditions
Human Papillomavirus Infection
All Listed Sponsors
collaborator
Kaiser Permanente
OTHER
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT01078220 - Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031) | Biotech Hunter | Biotech Hunter